Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Exjade® Reduces Cardiac Iron Burden in Chronically Transfused β-Thalassemia Patients: An MRI T2* Study.

J. Wood, A.A. Thompson, C. Paley, B. Kang, P. Giardina, P. Harmatz, J. Virkus, T. Coates

Blood (2007) 110 (11): 2781.

https://doi.org/10.1182/blood.V110.11.2781.2781

Published: 2007

Journal Articles

Long-Term Safety and Tolerability of the Once-Daily, Oral Iron Chelator Deferasirox (Exjade®, ICL670) in Patients with Transfusional Iron Overload.

M.D. Cappellini, P. Giardina, J. Porter, T. Coates, M.G. Della Porta, J. Siegel, E. Glimm, J. Ford

Blood (2006) 108 (11): 1768.

https://doi.org/10.1182/blood.V108.11.1768.1768

Published: 2006

Journal Articles

Satisfaction and Convenience of Chelation Therapy in Patients with Sickle Cell Disease (SCD): Comparison between Deferasirox (Exjade ® , ICL670) and Deferoxamine (DFO).

E. Vichinsky, R. Fischer, Z. Pakbaz, O. Onyekwere, J. Porter, P. Swerdlow, T. Coates, P. Lane, B. Files, B.U. Mueller, L. Coïc, G. Forni, L. Abetz, J.F. Baladi, C. Ressayre-Djaffer, I. Gathmann, D. Alberti, P. Marks

Blood (2005) 106 (11): 2334.

https://doi.org/10.1182/blood.V106.11.2334.2334

Published: 2005

Journal Articles

Comparison of LIC Obtained from Biopsy, BLS and R 2 -MRI in Iron Overloaded Patients with β-Thalassemia, Treated with Deferasirox (Exjade®, ICL670).

Blood (2005) 106 (11): 2689.

https://doi.org/10.1182/blood.V106.11.2689.2689

Published: 2005

Journal Articles

A Randomized, Controlled Phase II Trial in Sickle Cell Disease Patients with Chronic Iron Overload Demonstrates That the Once-Daily Oral Iron Chelator Deferasirox (Exjade ® , ICL670) Is Well Tolerated and Reduces Iron Burden.

E. Vichinsky, R. Fischer, E. Fung, O. Onyekwere, J. Porter, P. Swerdlow, T. Coates, P. Lane, B. Files, B. U. Mueller, F. Bernaudin, G. L. Forni, C. Ressayre-Djaffer, I. Gathmann, J. Holland, D. Alberti, P. Marks

Blood (2005) 106 (11): 313.

https://doi.org/10.1182/blood.V106.11.313.313

Published: 2005

Journal Articles

The 47-kD protein increased in neutrophil actin dysfunction with 47- and 89-kD protein abnormalities is lymphocyte-specific protein

T Howard, Y Li, M Torres, A Guerrero, T Coates

Blood (1994) 83 (1): 231–241.

https://doi.org/10.1182/blood.V83.1.231.231

Published: 1994

NARROW

Exjade® Reduces Cardiac Iron Burden in Chronically Transfused β-Thalassemia Patients: An MRI T2* Study.

Long-Term Safety and Tolerability of the Once-Daily, Oral Iron Chelator Deferasirox (Exjade®, ICL670) in Patients with Transfusional Iron Overload.

Satisfaction and Convenience of Chelation Therapy in Patients with Sickle Cell Disease (SCD): Comparison between Deferasirox (Exjade ® , ICL670) and Deferoxamine (DFO).

Comparison of LIC Obtained from Biopsy, BLS and R 2 -MRI in Iron Overloaded Patients with β-Thalassemia, Treated with Deferasirox (Exjade®, ICL670).

A Randomized, Controlled Phase II Trial in Sickle Cell Disease Patients with Chronic Iron Overload Demonstrates That the Once-Daily Oral Iron Chelator Deferasirox (Exjade ® , ICL670) Is Well Tolerated and Reduces Iron Burden.

The 47-kD protein increased in neutrophil actin dysfunction with 47- and 89-kD protein abnormalities is lymphocyte-specific protein

Email alerts

ASH Publications

American Society of Hematology

Exjade® Reduces Cardiac Iron Burden in Chronically Transfused β-Thalassemia Patients: An MRI T2* Study.

Long-Term Safety and Tolerability of the Once-Daily, Oral Iron Chelator Deferasirox (Exjade®, ICL670) in Patients with Transfusional Iron Overload.

Satisfaction and Convenience of Chelation Therapy in Patients with Sickle Cell Disease (SCD): Comparison between Deferasirox (Exjade ® , ICL670) and Deferoxamine (DFO).

Comparison of LIC Obtained from Biopsy, BLS and R 2 -MRI in Iron Overloaded Patients with β-Thalassemia, Treated with Deferasirox (Exjade®, ICL670).

A Randomized, Controlled Phase II Trial in Sickle Cell Disease Patients with Chronic Iron Overload Demonstrates That the Once-Daily Oral Iron Chelator Deferasirox (Exjade ® , ICL670) Is Well Tolerated and Reduces Iron Burden.

The 47-kD protein increased in neutrophil actin dysfunction with 47- and 89-kD protein abnormalities is lymphocyte-specific protein

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only